Are you Dr. Ingenito?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 42 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1023 Quincy Ave
Scranton, PA 18510Phone+1 310-279-7749
Summary
- Dr. Gary Ingenito, MD is a neurologist in Scranton, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
University of Miami/Jackson Health SystemResidency, Neurology, 1986 - 1989- University of Miami/Jackson Health SystemResidency, Neurological Surgery, 1984 - 1986
- University of Miami/Jackson Health SystemInternship, Transitional Year, 1983 - 1984
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1983
Certifications & Licensure
PA State Medical License 1991 - 2024
Clinical Trials
- Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Start of enrollment: 2018 Apr 18
Publications & Presentations
PubMed
- 8 citationsAmifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.Silvia Bonanno, Riccardo Giossi, Riccardo Zanin, Valentina Porcelli, Claudio Iannacone
Journal of Neurology. 2022-11-01 - 4 citationsTherapeutic efficacy of 3,4-Diaminopyridine phosphate on neuromuscular junction in Pompe disease.Cinzia Bragato, Flavia Blasevich, Gary Ingenito, Renato Mantegazza, Lorenzo Maggi
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2021-05-01 - 6 citationsTwo-Dimensional Proton Magnetic Resonance Spectroscopy versus J-Editing for GABA Quantification in Human Brain: Insights from a GABA-Aminotransferase Inhibitor StudyAndrew P. Prescot, James J. Prisciandaro, Steven R. Miller, Gary Ingenito, Douglas G. Kondo
Scientific Reports. 2018-09-04
Press Mentions
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to Be Presented at the Upcoming American Academy of Neurology 2023 Annual MeetingApril 20th, 2023- Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic EpilepsiesMarch 8th, 2023
- Catalyst Pharmaceuticals’ Firdapse® (Amifampridine Phosphate) Receives Marketing Approval in Canada for Patients with LEMSAugust 6th, 2020
- Join now to see all
